Loading...
In March 2026, the U.S. FDA approved a new 7.2-mg dose of injectable semaglutide (Wegovy HD) for adults with obesity. The previous maximal dose of this drug for weight reduction was 2.4 mg weekly.
Approval was based on two manufacturer-sponsored trials. One involved 1400 adults with obesity but no diabetes; the other involved 500 adults with obesity and type 2 diabetes, most of whom who had been taking oral diabetes drugs (but not insulin). The mean baseline weight in both trials was ≈110 kg.
In both trials, participants were randomized to weekly injections of placebo, semaglutide 2.4 mg, or semaglutide 7.2 mg. In the semaglutide groups, doses were gradually titrated to 2.4 mg over 4 months; a month later, the high-…